Trade Report: Today, Eli Lilly and Co. (LLY) is Grassi Investment Management’s 8th Largest Position

Today, Eli Lilly and Co. (LLY) is Grassi Investment Management’s 8th Largest Position

Grassi Investment Management reduced its stake in Eli Lilly and Co. (NYSE:LLY) by 0.3% during the third quarter, Holdings Channel reports. The institutional investor owned 111,439 shares of the company’s stock after selling 292 shares during the period. Eli Lilly and comprises about 1.7% of Grassi Investment Management’s portfolio, making the stock its 8th largest position. Grassi Investment Management’s holdings in Eli Lilly and were worth $8,944,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Benjamin F. Edwards & Company Inc. increased its stake in Eli Lilly and by 0.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,305 shares of the company’s stock valued at $260,000 after buying an additional 31 shares in the last quarter. Chevy Chase Trust Holdings Inc. increased its stake in Eli Lilly and by 1.1% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 836,508 shares of the company’s stock valued at $65,876,000 after buying an additional 8,987 shares in the last quarter. Exxonmobil Investment Management Inc. TX increased its stake in Eli Lilly and by 6.1% in the second quarter. Exxonmobil Investment Management Inc. TX now owns 251,441 shares of the company’s stock valued at $19,801,000 after buying an additional 14,451 shares in the last quarter. DNB Asset Management AS increased its stake in Eli Lilly and by 14.8% in the second quarter. DNB Asset Management AS now owns 235,250 shares of the company’s stock valued at $18,526,000 after buying an additional 30,400 shares in the last quarter. Finally, Washington Trust Bank increased its stake in Eli Lilly and by 7.7% in the second quarter. Washington Trust Bank now owns 7,118 shares of the company’s stock valued at $561,000 after buying an additional 509 shares in the last quarter. 73.93% of the stock is owned by institutional investors and hedge funds.

Shares of Eli Lilly and Co. (NYSE:LLY) traded down 2.78% during midday trading on Monday, reaching $67.20. 12,456,527 shares of the company traded hands. The company has a 50 day moving average price of $76.69 and a 200 day moving average price of $77.92. The company has a market capitalization of $71.08 billion, a PE ratio of 29.23 and a beta of 0.28. Eli Lilly and Co. has a 1-year low of $64.18 and a 1-year high of $88.16.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The company earned $5.19 billion during the quarter, compared to the consensus estimate of $4.23 billion. Eli Lilly and had a return on equity of 23.71% and a net margin of 11.73%. Eli Lilly and’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 earnings per share. On average, analysts expect that Eli Lilly and Co. will post $3.55 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be paid a $0.51 dividend. The ex-dividend date of this dividend is Thursday, November 10th. This represents a $2.04 dividend on an annualized basis and a yield of 2.95%. Eli Lilly and’s dividend payout ratio is currently 88.70%.

Several brokerages have recently commented on LLY. Citigroup Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a research note on Wednesday, August 3rd. Argus upped their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Leerink Swann reaffirmed a “buy” rating and set a $103.00 price objective on shares of Eli Lilly and in a research note on Sunday, October 9th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a research note on Monday, October 3rd. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $108.34.

In other Eli Lilly and news, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total value of $182,919.76. Following the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is currently owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Related posts

Leave a Comment